Skip to main content
Premium Trial:

Request an Annual Quote

WIN Consortium to Use Foundation Medicine Test in 200-Patient Trial Starting 2013


The Worldwide Innovative Networking Consortium in personalized cancer medicine plans to use Foundation Medicine's cancer genome profiling test in an upcoming clinical trial, the company said last week.

A company spokesperson told Clinical Sequencing News that the trial will involve 200 patients, who will be enrolled starting in early 2013. Each patient will be evaluated with the firm's sequencing-based test, FoundationOne, and be matched to a targeted therapy where possible.

The test "will allow physicians participating in this trial to test for alterations in clinically relevant genes known to be associated with human cancer and match these alterations with appropriate targeted therapies or clinical trials," said John Mendelsohn, chairman of the WIN Consortium, in a statement.

The WIN Consortium, which Foundation Medicine joined in March, is an international network of 22 academic institutions and companies. It was started by the Cancer Institute Gustave Roussy in France and the University of Texas MD Anderson Cancer Center and focuses on international biomarker-driven therapeutic clinical trials.

Foundation Medicine launched its test in May and said recently that it plans to conduct several clinical trials to show the test's efficacy and its impact on doctors' decisions (CSN 6/13/2012).

The test sequences 3,230 exons of 182 genes known to be mutated in solid tumors, as well as 37 introns from 14 genes known to be rearranged in these cancers.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.